4,5,6-三氯三嗪 | 70674-51-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 中文名称: 4,5,6-三氯三嗪
• 英文名称: s-trichlorotriazine
• 英文别名: 1,2,3-trichloro-4,5,6-triazine；trichloro-1,2,3-triazine；trichlorotriazine；trichloro-triazine；4,5,6-trichloro-[1,2,3]triazine；tri-chlorotriazine；4,5,6-trichlorotriazine
• CAS: 70674-51-0
• 化学式: C₃Cl₃N₃
• 分子量: 184.412
• InChiKey: LZKGFGLOQNSMBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,5,6-三氯三嗪 在 potassium fluoride 作用下， 生成 1,2,3-trifluoro-4,5,6-triazine
  参考文献：
  名称：

  全氟烷基-1,2,3-三嗪：对环氮的新型亲核攻击

  摘要：

  描述了三氟-和全氟异丙基-1,2,3-三嗪衍生物的合成，以及全氟烷基阴离子和苯基溴化镁对环氮的不寻常亲核攻击；发生2,3-二甲基丁二烯向环氮的向亲性加成和2,3-二甲基丁-2-烯的类似加成。

  DOI：

  10.1039/c39870001697
• 作为试剂：
  描述：

  7-溴庚酸甲酯 在 sodium sulfate 、 三乙胺 、 4,5,6-三氯三嗪 作用下， 以 水 、 丙酮 为溶剂， 反应 17.75h， 生成 7-(3,4-dihydrocarbostyril-6-ylsulfamoyl)heptanoic acid methyl ester
  参考文献：
  名称：

  Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors

  摘要：

  Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038μM; HDAC2, 0.0082μM; HDAC3, 0.015μM; HDAC8, 0.0060μM; HDAC4, 0.058μM; HDAC9, 0.0052μM; HDAC6, 0.058μM). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process.

  DOI：

  10.1016/j.bmc.2014.05.001

文献信息

• Triazine oligomers as photostabilising agents
  申请人：3V SIGMA S.p.A

  公开号：EP2759539A1

  公开（公告）日：2014-07-30

  Disclosed are oligomeric compounds obtained by condensation of the compound of formula (I) with itself wherein R1 and R2 are C1-C22 alkyl, isoalkyl or cycloalkyl groups.

  披露了通过化合物（I）与其自身缩合而得到的寡聚化合物， 其中R1和R2为C1-C22烷基、异构烷基或环烷基基团。
• Modified Human Apolipoprotein A-1 and Their Uses
  申请人：Knudsen Nick

  公开号：US20110178029A1

  公开（公告）日：2011-07-21

  Modified human apolipoprotein A-I polypeptides and uses thereof are provided.

  提供了改良的人类载脂蛋白A-I多肽及其用途。
• MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES
  申请人：KRAYNOV Vadim

  公开号：US20120046229A1

  公开（公告）日：2012-02-23

  Modified relaxin polypeptides and their uses thereof are provided

  修改后的弛缓素多肽及其用途
• Modified Leptin Polypeptides and Their Uses
  申请人：Kraynov Vadim

  公开号：US20120149636A1

  公开（公告）日：2012-06-14

  Modified human leptin polypeptides and uses thereof are provided.

  提供了改良的人类瘦素多肽及其用途。
• [EN] THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPLEXES DE MÉTAL THÉRAPEUTIQUES ET LIGANDS, LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV OREGON STATE

  公开号：WO2019046761A1

  公开（公告）日：2019-03-07

  Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and/or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.

  本文披露了一种化合物实施例，可用于治疗各种疾病，特别是神经系统疾病、运动神经元疾病、铜缺乏相关疾病和/或线粒体缺陷。本文还披露了这些化合物实施例可用于PET方法。本文还披露了制备和使用这些化合物实施例的方法实施例，以及包含所披露的化合物实施例的药物配方。